|
|
|
| 气管内应用布地奈德联合肺表面活性物质预防极早产儿支气管肺发育不良的研究进展 |
| 朱曦怡, 李福兵 |
| 广西壮族自治区人民医院儿科,广西 南宁 530021 |
|
[1] 蔡志勇,刘进娣,卞洪亮,等.不同时间应用“气管插管-使用肺表面活性物质-拔管使用持续呼吸道正压通气”技术在呼吸窘迫综合征高危早产儿中的疗效[J].中华实用儿科临床杂志,2016,31(2):101-104.
[2] COSTELOE K L,HENNESSY E M,HAIDER S,et al. Short term outcomes after extreme preterm birth in England:comparison of two birth cohorts in 1995 and 2006 (the EPICure studies)[J].BMJ,2012,345:e7976.
[3] MCEVOY C T,JAIN L,SCHMIDT B,et al. Bronchopulmonary dysplasia:NHLBI workshop on the primary prevention of chronic lung diseases[J].Ann Am Thorac Soc,2014,11(Suppl 3):S146-S153.
[4] DOYLE L W,EHRENKRANZ R A,HALLIDAY H L. Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants:a systematic review[J].Neonatology,2010,98(3):217-224.
[5] 杜立中.早产儿支气管肺发育不良的防治新理念[J].中国实用儿科杂志,2014,29(1):12-15.
[6] SEGER N,SOLL R. Animal derived surfactant extract for treatment of respiratory distress syndrome[J].Cochrane Database Syst Rev,2009,5(2):CD007836.
[7] LEMYRE B,LAUGHON M,BOSE C,et al. Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants[J].Cochrane Database Syst Rev,2016,12(12):CD005384.
[8] SU B H,WATANABE T,SHIMIZU M,et al. Doppler assessment of pulmonary pressure in neonates at risk of chronic lung disease[J].Arch Dis Child Fetal Neonatal Ed,1997,77(1):F23-F27.
[9] SCHMIDT B,ROBERTS R S,DAVIS P,et al. Caffeine therapy for apnea of prematurity[J].N Engl J Med,2006,354(20):2112-2121.
[10] HASCOET J M,FRESSON J,CLARIS O,et al. The safety and efficacy of nitric oxide therapy in preterm infants[J].J Pediatr,2005,146(3):318-323.
[11] BALLARD R A,KELLER R L,BLACK D M,et al. Randomized trial of late surfactant treatment in ventilated preterm infants receiving inhaled nitric oxide[J].J Pediatr,2016,168:23-29.
[12] MATALON S,HU P,ISCHIROPOULOS H,et al. Peroxynitrite inhibition of oxygen consumption and ion transport in alveolar type Ⅱ pneumocytes[J].Chest,1994,105(3 Suppl):74S.
[13] HAMON I,HASCOET J M. Perinatal corticotherapy:updates[J].J Gynecol Obstet Biol Reprod,2001,30(6 Suppl):S50-S53.
[14] WRIGHT C J,KIRPALANI H.Targeting inflammation to prevent bronchopulmonary dysplasis:can new insights be translated into therapies?[J].Pediatrics,2011,128(1):111-126.
[15] RAYMONDOS K,LEUWER M,HASLAM P L,et al. Compositional,structural,and functional alterations in pulmonary surfactant in surgical patients after the early onset of systemic inflammatory response syndrome or sepsis[J].Crit Care Med,1999,27(1):82-89.
[16] THALEN A,BRATTSAND R,ANDERSSON P H. Development of glucocorticos-teroids with enhanced ratio between topical and systemic effects[J].Acta Derm Venereol Suppl (Stockh),1989,151:11-19.
[17] YEH T F,LIN H C,CHANG C H,et al.Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants:a pilot study[J].Pediatrics,2008,121(5):e1310-e1318.
[18] YEH T F. Intratracheal administration of Budesonide/Surfactant to prevent bronchopulmonary dysplasia[J].Am J Respir Crit Care Med,2016,193(1):86-95.
[19] 杜凤玲,董文斌,赵帅.布地奈德联合猪肺磷脂注射液预防早产儿[J].中华实用儿科临床杂志,2016,31(11):846-850.
[20] 饶军,程贤高,李晓春.布地奈德联合肺表面活性物质气管内注入防治早产儿支气管肺发育不良的效果[J].医学信息,2020,33(23):147-149.
[21] 晏路标,韩树萍,储晓彬,等. 肺表面活性物质联合布地奈德对急性呼吸窘迫综合征极低出生体质量儿肺功能的影响[J].实用儿科临床杂志,2011,26(18):1400-1402.
[22] ROBERTS J K,STOCKMANN C,DAHL M J,et al. Pharmacokinetics of budesonide administered with surfactant in premature lambs:implications for neonatal clinical trials[J].Curr Clin Pharmacol,2016,11(1):53-61.
[23] HALLIDAY H L,EHRENKRANZ R A,DOYLE L W. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants[J].Cochrane Database Syst Rev,2009,5(1):CD001145.
[24] FAJARDO C,LEVIN D,GARCIA M,et al. Surfactant versus saline as a vehicle for corticosteroid delivery to the lungs of ventilated rabbits[J].Pediatr Res,1998,43:542-547.
[25] 刘东成,劳庆禄,陆妹,等.早期气管内滴入以氨溴索为载体的布地奈德防治早产儿呼吸窘迫综合征的效果研究[J].中国全科医学,2012,15(35):4140-4142.
[26] 邓黎静,彭华保,龚晓琴.布地奈德联合肺表面活性物质治疗重症呼吸窘迫综合征对支气管肺发育不良的影响[J].中华新生儿科杂志,2017,32(5):361-364.
[27] 朱曦怡,温志红,李福兵.布地奈德联合肺表面活性物质对早产儿支气管肺发育不良的临床疗效[J].中国中西医结合儿科学,2021,13(4):185-188. |
| [1] |
姬妍娜, 邢小艳. 延安地区结核病患者结核分枝杆菌的成簇特征及传播危险因素[J]. 医学临床研究, 2022, 39(7): 988-991. |
| [2] |
任爱霞, 孙艳林, 闫晓红, 王磊. 益智仁提取物对糖尿病肾病小鼠肾氧化应激损伤的影响及机制研究[J]. 医学临床研究, 2022, 39(7): 1029-1032. |
| [3] |
连鹏, 贺映波. 1.5 T MRI不同b值DWI在乳腺疾病诊断中的应用价值[J]. 医学临床研究, 2022, 39(7): 1058-1060. |
| [4] |
陈伟, 董自然, 王琴琴. 利奈唑胺联合头孢噻肟钠治疗新生儿化脓性脑膜炎的临床效果及对患儿神经损伤因子、IL-12、SAA水平的影响[J]. 医学临床研究, 2022, 39(7): 1072-1074. |
| [5] |
辛芳妮, 蔺敏. sTREM-1、HMGB1在慢性阻塞性肺疾病急性加重患者血清中的表达水平及其意义[J]. 医学临床研究, 2022, 39(7): 1113-1115. |
| [6] |
刘聪, 成玮, 曾玉琴, 詹济舟, 肖影, 陈平. 慢性阻塞性肺疾病戒烟者和目前吸烟者的临床特点[J]. 医学临床研究, 2022, 39(6): 808-811. |
| [7] |
易荣, 许玉竹, 冯玲, 曾玉琴, 周军, 颜又新, 刘毅, 陈平. 双联支气管扩张剂治疗症状型慢性阻塞性肺疾病患者的有效性和安全性[J]. 医学临床研究, 2022, 39(5): 641-643. |
| [8] |
赵静, 邵建强. 右美托咪定滴鼻与咪达唑仑口服在儿童门诊口腔治疗中的应用效果比较[J]. 医学临床研究, 2022, 39(5): 768-770. |
| [9] |
张沛, 曹绥琳. 中青年与老年终末期肾病透析患者体内微量元素水平比较[J]. 医学临床研究, 2022, 39(5): 782-784. |
| [10] |
张粉霞, 冯成虎, 吴晓玉, 张龙, 屈菊梅, 常祎, 赵新. 枸橼酸咖啡因联合无创呼吸支持模式治疗新生儿重症吸入性肺炎的临床疗效及安全性[J]. 医学临床研究, 2022, 39(4): 524-527. |
| [11] |
吕建宁, 李琼. 胸腺肽α1对铜绿假单胞菌诱导的支气管扩张大鼠免疫失衡的干预作用[J]. 医学临床研究, 2022, 39(4): 535-538. |
| [12] |
王瑞娟, 张楠. 高血压合并慢性肾脏病患者与单纯高血压患者临床特征比较[J]. 医学临床研究, 2022, 39(4): 539-541. |
| [13] |
田晓花, 贾海娟. PGR联合血清肿瘤标志物检测在胃良性疾病与胃癌中的鉴别诊断价值[J]. 医学临床研究, 2022, 39(4): 579-581. |
| [14] |
窦丽, 苗润燕. 间变淋巴瘤激酶对子宫炎性肌纤维母细胞瘤的诊断价值[J]. 医学临床研究, 2022, 39(4): 568-571. |
| [15] |
廖占玲, 安国印, 吴晶晶, 陈润祥. 冠心病患者血清BMP6、TGF-β1水平与冠状动脉病变程度的相关性[J]. 医学临床研究, 2022, 39(3): 435-438. |
|
|
|
|
2022, Vol. 39 
